Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study
- PMID: 31880010
- DOI: 10.1111/apt.15600
Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study
Comment on
-
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.Aliment Pharmacol Ther. 2020 Jan;51(1):129-138. doi: 10.1111/apt.15539. Epub 2019 Nov 6. Aliment Pharmacol Ther. 2020. PMID: 31692017
References
REFERENCES
-
- Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:941-950.
-
- Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114:1172-1175.
-
- Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease (IBD) in pregnancy clinical care pathway - a report from the american gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508-1524.
-
- Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51:129-138.
-
- Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with crohn’s disease and birth outcomes: A regional danish cohort study. Am J Gastroenterol. 2007;102:1947-1954.